Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVAH Aveanna Healthcare	$7.47 +6.1%	$4.97	$3.67 ▼ $7.69	$1.56B	1.95	1.74 million shs	1.55 million shs
PSNL Personalis	$4.83 +3.6%	$5.94	$2.83 ▼ $7.79	$428.31M	1.86	1.10 million shs	1.30 million shs
TDOC Teladoc Health	$7.67 +6.7%	$7.73	$6.35 ▼ $15.21	$1.36B	1.76	7.19 million shs	6.04 million shs
VRDN Viridian Therapeutics	$19.23 +6.7%	$16.60	$9.90 ▼ $27.20	$1.57B	0.42	841,737 shs	1.40 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVAH Aveanna Healthcare	0.00%	+5.51%	+89.59%	+40.41%	+38.46%
PSNL Personalis	0.00%	+5.00%	-28.02%	+1.05%	-23.82%
TDOC Teladoc Health	0.00%	+2.18%	-6.36%	+12.60%	+4.05%
VRDN Viridian Therapeutics	0.00%	+3.72%	+9.95%	+41.71%	+23.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVAH Aveanna Healthcare	1.9246 of 5 stars	2.3	4.0	0.0	2.6	2.5	0.0
PSNL Personalis	4.1822 of 5 stars	3.5	1.0	4.2	3.2	2.5	0.6
TDOC Teladoc Health	3.0799 of 5 stars	3.2	3.0	0.0	2.5	2.5	1.3
VRDN Viridian Therapeutics	1.5652 of 5 stars	4.4	0.0	0.0	1.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVAH Aveanna Healthcare	2.60	Moderate Buy	$7.50	0.40% Upside
PSNL Personalis	3.00	Buy	$7.42	53.55% Upside
TDOC Teladoc Health	2.33	Hold	$9.75	27.05% Upside
VRDN Viridian Therapeutics	2.89	Moderate Buy	$37.00	92.41% Upside

Current Analyst Ratings Breakdown

Latest PSNL, VRDN, AVAH, and TDOC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AVAH Aveanna Healthcare	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$5.50 ➝ $9.50
8/19/2025	AVAH Aveanna Healthcare	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$6.75 ➝ $8.00
8/12/2025	AVAH Aveanna Healthcare	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$5.00 ➝ $6.75
8/11/2025	AVAH Aveanna Healthcare	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$9.00
8/7/2025	VRDN Viridian Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00
8/7/2025	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $41.00
8/7/2025	VRDN Viridian Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$27.00 ➝ $26.00
8/7/2025	VRDN Viridian Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $32.00
8/6/2025	PSNL Personalis	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$6.00
8/6/2025	PSNL Personalis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.50
8/6/2025	VRDN Viridian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVAH Aveanna Healthcare	$2.02B	0.77	$0.16 per share	45.56	($0.06) per share	-124.50
PSNL Personalis	$84.61M	5.06	N/A	N/A	$2.15 per share	2.25
TDOC Teladoc Health	$2.57B	0.53	$5.56 per share	1.38	$8.05 per share	0.95
VRDN Viridian Therapeutics	$300K	5,234.41	N/A	N/A	$4.00 per share	4.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVAH Aveanna Healthcare	-$10.93M	$0.08	93.38	∞	N/A	0.85%	-54.56%	3.17%	11/6/2025 (Estimated)
PSNL Personalis	-$81.28M	-$1.28	N/A	N/A	N/A	-113.70%	-47.57%	-35.05%	11/5/2025 (Estimated)
TDOC Teladoc Health	-$1.00B	-$1.19	N/A	N/A	N/A	-8.16%	-10.13%	-4.43%	10/29/2025 (Estimated)
VRDN Viridian Therapeutics	-$269.95M	-$3.83	N/A	N/A	N/A	-112,806.88%	-78.95%	-49.91%	11/11/2025 (Estimated)

Latest PSNL, VRDN, AVAH, and TDOC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	VRDN Viridian Therapeutics	-$1.00	-$1.00	N/A	-$1.00	$0.05 million	$0.08 million
8/5/2025	Q2 2025	PSNL Personalis	-$0.25	-$0.23	+$0.02	-$0.23	$20.12 million	$17.20 million
7/29/2025	Q2 2025	TDOC Teladoc Health	-$0.27	-$0.19	+$0.08	-$0.19	$621.91 million	$631.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVAH Aveanna Healthcare	N/A	N/A	N/A	N/A	N/A
PSNL Personalis	N/A	N/A	N/A	N/A	N/A
TDOC Teladoc Health	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVAH Aveanna Healthcare	N/A	1.09	1.09
PSNL Personalis	N/A	6.09	5.92
TDOC Teladoc Health	0.70	2.67	2.58
VRDN Viridian Therapeutics	0.04	11.01	11.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVAH Aveanna Healthcare	87.96%
PSNL Personalis	61.91%
TDOC Teladoc Health	76.82%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVAH Aveanna Healthcare	7.80%
PSNL Personalis	3.80%
TDOC Teladoc Health	0.58%
VRDN Viridian Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVAH Aveanna Healthcare	33,500	208.90 million	192.60 million	Optionable
PSNL Personalis	400	88.68 million	85.31 million	Optionable
TDOC Teladoc Health	5,500	176.69 million	175.67 million	Optionable
VRDN Viridian Therapeutics	50	81.66 million	80.37 million	Optionable

PSNL, VRDN, AVAH, and TDOC Headlines

Recent News About These Companies

Viridian Therapeutics, Inc. $VRDN Shares Purchased by Candriam S.C.A.

August 24 at 6:17 AM | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) & Y-mAbs Therapeutics (NASDAQ:YMAB) Critical Analysis

August 21 at 4:13 AM | americanbankingnews.com

Viridian Therapeutics (VRDN) Expected to Announce Earnings on Thursday

August 13, 2025 | americanbankingnews.com

HC Wainwright Issues Optimistic Estimate for VRDN Earnings

August 11, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Outlook for VRDN Earnings

August 11, 2025 | marketbeat.com

Lifesci Capital Has Negative Estimate for VRDN Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Research Analysts Boost Earnings Estimates for VRDN

August 11, 2025 | marketbeat.com

Wedbush Lowers Earnings Estimates for Viridian Therapeutics

August 9, 2025 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Hits Expectations

August 9, 2025 | marketbeat.com

The Goldman Sachs Group Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

August 8, 2025 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $41.00 at Royal Bank Of Canada

August 8, 2025 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $26.00 at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Oppenheimer Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $32.00

August 8, 2025 | marketbeat.com

Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $34.00

August 7, 2025 | marketbeat.com

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

August 7, 2025 | benzinga.com

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan

August 7, 2025 | ophthalmologytimes.comO

Viridian Therapeutics (VRDN) to Release Earnings on Thursday

August 7, 2025 | marketbeat.com

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

August 6, 2025 | finance.yahoo.com

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2025 | zacks.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 3.5% - Here's What Happened

August 5, 2025 | marketbeat.com

J. Safra Sarasin Holding AG Has $980,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL, VRDN, AVAH, and TDOC Company Descriptions

Aveanna Healthcare NASDAQ:AVAH

$7.47 +0.43 (+6.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.36 -0.11 (-1.47%)

As of 08/22/2025 07:49 PM Eastern

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Personalis NASDAQ:PSNL

$4.83 +0.17 (+3.65%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.88 +0.05 (+1.14%)

As of 08/22/2025 07:31 PM Eastern

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Teladoc Health NYSE:TDOC

$7.67 +0.48 (+6.73%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$7.68 +0.01 (+0.14%)

As of 08/22/2025 08:00 PM Eastern

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

Viridian Therapeutics NASDAQ:VRDN

$19.23 +1.21 (+6.71%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.09 -0.14 (-0.73%)

As of 08/22/2025 07:53 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time